Irland - engelsk - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - erythromycin -

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - memantine hydrochloride 10mg; memantine hydrochloride 10mg - film coated tablet - 10 mg - active: memantine hydrochloride 10mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate methacrylic acid - ethyl acrylate copolymer microcrystalline cellulose polysorbate 80 purified talc   purified water simeticone sodium laurilsulfate triacetin active: memantine hydrochloride 10mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose titanium dioxide - treatment of patients with moderate to severe alzheimer's disease

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - somatropin 8 mg/ml - solution for injection - 8 mg/ml - active: somatropin 8 mg/ml excipient: citric acid phenol poloxamer sodium hydroxide sucrose water for injection - saizen is indicated for: 1. growth failure in children due to human growth hormone deficiency. 2. growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis. 3.saizen is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfil the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. 4. growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fexofenadine hydrochloride 120mg;   - tablet - 120 mg - active: fexofenadine hydrochloride 120mg   excipient: carmellose colloidal silicon dioxide ferric oxide, pink hypromellose e-15 hypromellose e-5 iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose povidone pregelatinised maize starch titanium dioxide - the treatment of seasonal allergic rhinitis in adults and children 12 years of age

Irland - engelsk - HPRA (Health Products Regulatory Authority)

billev pharma aps - atorvastatin calcium - film coated tablet - 40 milligram

Irland - engelsk - HPRA (Health Products Regulatory Authority)

billev pharma aps - atorvastatin calcium - film coated tablet - 10 milligram

Irland - engelsk - HPRA (Health Products Regulatory Authority)

billev pharma aps - atorvastatin calcium - film coated tablet - 20 milligram

Irland - engelsk - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

gw pharma ltd - cannabidiol; dronabinol - spray - 2.5mg/1dose ; 2.7mg/1dose